|
Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). |
| |
|
Consulting or Advisory Role - Genentech/Roche |
Speakers' Bureau - Genentech |
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst) |
| |
|
|
Stock and Other Ownership Interests - Bayer |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Helsinn Therapeutics (Inst); Kite/Gilead (Inst) |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Helsinn Therapeutics (Inst); Kite/Gilead (Inst) |
Other Relationship - Pharmerit |
| |
|
Research Funding - Bayer (Inst); Daiichi Sankyo (Inst) |
| |
|
Research Funding - Bayer (Inst); Celgene (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Novartis (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Bayer; Pfizer |